Catalysts

Catalysts - What Can Move the Stock

The next six months hinge on a single number printed twice: the Health Benefits Ratio in Q1 2026 (released tomorrow morning, April 28) and again in Q2 2026 (late July). Every other event on the calendar — the May 12 annual meeting, the BofA / Jefferies / Goldman healthcare conferences in May–June, the watchpoint on a $4.0B Part D receivable facility, and an unresolved securities class action — orbits those two HBR prints. The calendar is dense for the next 90 days and quieter thereafter; this is a "decide on the data, not the calendar" setup.

Hard-dated events (next 6m)

High-impact catalysts

Days to next hard date

Signal quality (1-5)

**The single most important event is tomorrow.** Q1 2026 results print pre-market on April 28 with consensus at $1.85 adjusted EPS, $47.47B revenue, and a Health Benefits Ratio of 89.3%. Because the Q4 2025 Marketplace HBR was 95.4% and the FY2026 guide of greater than $3.00 EPS depends on mid-30% rate hikes pulling that ratio back toward 87%, the Q1 print is the first hard test of management's repricing math. A Marketplace HBR sub-89% with Medicaid HBR at or below 93% reaffirms the $3.00 floor; either above the bear thresholds (Marketplace above 90%, Medicaid above 93.5%) cuts directly into the recovery thesis.

Ranked Catalyst Timeline

No Results

The ranking is decision-value, not chronology: items 1, 3, and 4 are the only catalysts that can change underwriting on their own. Item 2 (the AGM) matters because two of CNC's three governance flags — comp design and the Burdick related-party question — vote on May 12. Items 5–6 are messaging windows that can pre-trade the Q2 print. Items 7–10 are continuous watchpoints rather than events; they show up in 10-Q footnotes, not headlines.

Impact Matrix

No Results

Next 90 Days

No Results

The 90 days are front-loaded: four of the five hard events fall within the next 45 days. After mid-June the calendar goes quiet until the late-July Q2 print. There is no investor day on the schedule and no formal product/regulatory milestone within six months — this stock will be priced on the data prints, not on staged disclosure.

What Would Change the View

Three observable signals over the next six months would reshape the debate. First, the segment HBRs across the next two quarterly prints — a Marketplace HBR sub-89% paired with Medicaid at or below 93% in both Q1 and Q2 ends the bear's "structural step-up" thesis and forces consensus models off $3.00 toward $4.50–5.00, the Bull's primary catalyst. Second, the disclosure status of the $4.0B Part D receivable purchase agreement in each 10-Q — drawing the facility quietly is the Bear's forensic smoking gun and would convert the 2025 cash-flow rebound from "real" to "engineered"; leaving it undrawn through FY2026 removes the single largest forensic anchor. Third, insider behavior post-Q1 — open-market buying by CEO London or CFO Asher at $40 would be the conviction signal absent in the 2025 reset, while continued absence (or any C-suite selling) confirms the people work's read that the team is managing through, not buying. Resolution of the securities class action and any SEC enforcement step is a tail risk that can re-rate the stock independent of operating performance, but the operating signals come first and are the path most likely to force the debate to update.

Generated Apr 27, 2026 16:45 UTC